Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN7A | Q01118 | 3/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 6/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4091084 | 0.99 | TBK1 (0.41) | SCN7AHRH3SCN5ASCN2ASCN8A | |
| SCHEMBL4085342 | 0.98 | TBK1 (0.40) | SCN7AHRH3SCN5ASCN2ASCN8A | |
| SCHEMBL5381490 | 0.91 | BACE1 (0.43) | HRH3TBK1ESR1KCNH2ESR2 | |
| SCHEMBL4079707 | 0.89 | HRH3 (0.49) | HRH3HRH2HRH1ESR1 | |
| SCHEMBL4082983 | 0.89 | SLC6A2 (0.38) | KCNH2 | |
| SCHEMBL4083905 | 0.88 | HRH3 (0.44) | HRH3HRH2HRH1ESR1 | |
| SCHEMBL4084194 | 0.88 | EGLN2 (0.42) | SCN7AHRH3SCN5ASCN2ASCN8A | |
| SCHEMBL4079425 | 0.88 | HRH3 (0.47) | HRH3HRH2HRH1ESR1 | |
| SCHEMBL4094125 | 0.87 | CMKLR1 (0.34) | SCN7AHRH3SCN5ASCN2ASCN8A | |
| SCHEMBL4089143 | 0.87 | CHRNB1 (0.41) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| EP-1692128-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | SCN7A 2498/4885HRH3 2504/4885SCN5A 1747/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | SCN7A 2639/4885HRH3 2769/4885SCN5A 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.